Last reviewed · How we verify
MEDI0562
At a glance
| Generic name | MEDI0562 |
|---|---|
| Also known as | Surgical Resection |
| Sponsor | Providence Health & Services |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial in Patients With Relapsed Ovarian Cancer (PHASE2)
- Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma (PHASE1)
- A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors (PHASE1)
- A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI0562 CI brief — competitive landscape report
- MEDI0562 updates RSS · CI watch RSS
- Providence Health & Services portfolio CI